Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its Phase II trial. The strategic combination of IL-33 inhibitors with ...

Omalizumab, a humanized monoclonal anti-IgE antibody, demonstrated rapid dose-dependent suppression of free IgE levels in the serum that improved quality of life (QOL) and both clinically and ...

In the real-world, open-label study of mechanisms of action of omalizumab in severe asthma (SoMOSA), Djukanovi and colleagues assessed 191 patients with severe uncontrolled atopic asthma receiving ...

The phase 3 OUtMATCH study (ClinicalTrials.gov Identifier: NCT03881696) is a 3-stage, randomized, double-blind, placebo-controlled study evaluating omalizumab in patients aged 1 to 55 years with ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

OIT dropouts strongly influenced results. In an intention-to-treat analysis, which includes all participants, almost twice as many participants in the omalizumab group (21/58 or 36%) successfully ...

BALTIMORE, Md. (Ivanhoe Newswire) – Milk, eggs, peanuts — they are the top three when it comes to food allergies. According to researchers, up to eight percent of kids and 10 percent of adults ...

Omalizumab may decrease antitussive use in patients with allergic asthma, according to a study presented at the American Thoracic Society (ATS) International Conference 2022 held in San Francisco ...

Omalizumab survival rates decreased from 76% after 1 year to 39% after 7 years. The main reasons for discontinuation were well-controlled disease (65%), ineffectiveness (18%) and adverse events (4%).

14-year-old Ellie Rubinfeld has lightening reflexes, and she also has to keep her eye on the ball when it comes to what she eats. “I can’t have eggs, peanuts, tree nuts and sesame,” she said.